Biomedical subjects

Georg Wieselthaler

Publications and source records attributed to Georg Wieselthaler.

16 recordsLinked to original sources

PubMed2006

First clinical experience with an automatic control system for rotary blood pumps during ergometry and right-heart catheterization.

BACKGROUND: At present, most clinically implanted rotary blood pumps are operated at constant speed and adjusted by the physician. It is generally assumed that an adaptation of pump speed to the patient's physiologic requirements would be beneficial. The data provided in this paper, based on hemodynamic and spirometric data during exercise in which a pre-load-sensitive control was used, lend quantitative support to this assumption. METHODS: An automatic speed control was developed and implemented with Matlab on a dSpace controller board. The system uses pump speed, pump power, and pump flow as its only input signals. It was connected to the clinical hardware of the DeBakey VAD System. The control is pre-load-sensitive and uses an expert system to detect excessive unloading and eventual suction. This system was used to quantify the cardiovascular reaction of patients to both automatically controlled and constant pump speed. A sub-group of 5 patients underwent bicycle ergometry with Swan-Ganz catheterization and spiroergometry. RESULTS: The automatic, closed-loop speed control showed robust and stable performance. It provided an increase in pump flow (+0.94 +/- 0.5 liters/min, p < 0.05) compared with constant-speed mode in response to physical activity. Pulmonary arterial (PAP) and capillary wedge pressure (PCWP) clearly decreased (-7.4 +/- 4.1 mm Hg for PAP and -8.3 +/- 4.2 mm Hg for PCWP, p < 0.05), and venous oxygen saturation moderately increased (+5.2%). CONCLUSION: An automatic speed-control system for rotary blood pumps was developed and demonstrated by spiroergometry to be appropriately responsive to physiologic demand.

Algorithms↗

PubMed2006

Advanced suction detection for an axial flow pump.

An automatic detection system for ventricular collapse was developed and tested in a first clinical trial as part of a physiological speed control concept for axial flow pumps. From this clinical experience, and based on the acquired data during this trial, an optimization of the developed system was performed. An already-existing database of 784 individual cases was extended. For harmonization of this database an additional 412 snap files were extracted from continuous data recordings and classified manually using a standardized procedure. The already-developed and clinically tested algorithms were supplemented by one additional indicator derived from a preexisting criterion. One threshold value was replaced by application of a numerically optimized nonlinear characteristic curve dependent on heart rate. Finally, in a multidimensional optimization process of the entire suction detection system, 7 individual indicators were adjusted by using 17 independent threshold values. The optimization criteria were applied using a three-level hierarchical system. Within the final database consisting of 1196 snap shots the overall amount of maldetections could be reduced to 23 cases including 5 false positive events (0.42%) and 18 false negative decisions (1.5%). By application of the clinical experience from the first clinical trial of a physiologic control system it became possible to optimize the sensitivity and specificity of the suction detection system to unprecedented accuracy.

Algorithms↗

PubMed2005

Physiology of continuous blood flow in recipients of rotary cardiac assist devices.

The beating heart and the resultant pulse wave have been a symbol of life for centuries. The development history of roller pumps for cardiopulmonary bypass shows that the human body tolerates non-pulsatile blood flow, at least for short-term support. Over the last few years, many types of rotary blood pumps have been developed for clinical use in patients requiring mid- to long-term support. Although early clinical experiences in patients with long-term support have been promising, the matter of whether pulsatile flow is needed or not remains controversial. Therefore, this review summarizes the observed clinical consequences of continuous blood flow in patients supported by rotary blood pumps and relates these consequences to underlying experimental studies.

Animals↗

PubMed2005

Development of a reliable automatic speed control system for rotary blood pumps.

BACKGROUND: Axial blood pumps have been very successfully introduced into the arena of prolonged clinical support. However, they do not offer inherent load-responsive mechanisms for adjusting pumping performance to venous return and changes in physiologic requirements of the patient. To provide for these adjustments we developed an algorithm for demand-responsive pump control based on a reliable suction detection system. METHODS: A PC-based system that analyzes pump performance based on available flow, heart rate and short-term performance history was developed. The physician defines levels of "desired flow" at rest and during exercise, depending on heart rate. In case this desired flow cannot be maintained due to limited venous return, the maximal available flow level is determined from an analysis of the actual pump data (flow, speed and power consumption). An expert system continuously checks the flow signal for any indication of suction. Periodic speed variations then adapt pump performance to the patient's condition. RESULTS: First, stability and functionality were proven under various settings in vitro. The algorithms were then tested in 15 patients in intensive care, in the standard ward, and during bicycle exercise. The system reacted properly to demand changes, at exercise level, in response to coughing and at various Valsalva maneuvers. Suction could also be successfully prevented during severe arrhythmia and in patients with critical cardiac geometry. Exercise tests showed decreases in pulmonary arterial pressure (-22 +/- 9.9%) and pulmonary capillary wedge pressure (-42 +/- 18.54%), and an increase in pump flow (19 +/- 9.5%) and workload (8 +/- 6.1%), all when compared with constant-speed pumping. CONCLUSIONS: A closed-loop control system equipped with an expert system for reliable suction detection was developed that improves response to change in venous return for rotary pump recipients. The system was robust, stable and safe under a wide range of everyday living conditions.

Algorithms↗

PubMed2004

Extracorporeal membrane oxygenation is superior to right ventricular assist device for acute right ventricular failure after heart transplantation.

BACKGROUND: Acute right ventricular failure after heart transplantation is a life-threatening condition, and sometimes the use of mechanical circulatory support is inevitable. The aim of this retrospective study was to investigate the effectiveness of two different mechanical circulatory support systems for this indication. METHODS: From 1984 to 2003, 28 heart transplant recipients exhibited right ventricular failure resistant to drug therapy. Right ventricular assist device (n = 15) or extracorporeal membrane oxygenation (n = 13) was implanted to support the failing heart. RESULTS: Overall in-hospital survival was 43%. In the right ventricular assist device group, only 2 patients (13%) could be weaned from mechanical circulatory support compared with 10 patients (77%) in the extracorporeal membrane oxygenation group (p = 0.001). Retransplantation was necessary in 6 patients in the right ventricular assist device group and in 1 patient in the extracorporeal membrane oxygenation group (p = 0.049). There was no difference in patient survival between groups, but graft survival was significantly better in the extracorporeal membrane oxygenation group (p = 0.005). CONCLUSIONS: In view of these results, extracorporeal membrane oxygenation seems to be the better option as mechanical circulatory support for right ventricular failure in heart transplantation.

Aged↗

PubMed2004

Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation.

BACKGROUND: Cytomegalovirus (CMV) has long been recognized as the most common opportunistic pathogen in transplant recipients. The use of post-detection antiviral treatment of CMV as a strategy to prevent disease in cardiac recipients is becoming the standard policy. Valganciclovir is an oral pro-drug of ganciclovir, with a 10-fold greater bioavailability than oral gancyclovir. PATIENTS AND METHODS: We reported our first experience with 8 patients (3 female, 45.0 +/- 10.5 years old, non-CMV mismatched) who underwent cardiac transplantation and had positive results of CMV polymerase chain reaction (PCR) within first 6 weeks after transplantation without concomitant CMV disease. These patients received valganciclovir in dosage 450 to 900 mg daily depending on renal function for 3 weeks. Standard immunosuppressive regimen consisted of cyclosporin A, MMF and corticosteroids, and was not changed after detection of CMV infection. In one patient we used sirolimus with respectively reduced dosage of cyclosporin A. Weekly measurements of CMV-PCR were performed to observe results of therapy. RESULTS: After 1 week of valganciclovir therapy CMV-PCR plasma concentration in all patients decreased significantly (2,105 copies/ml vs 400 copies/ml; p < 0.0001). No relapse of CMV infection has been detected after completing of valganciclovir therapy with follow up duration of 9.0 +/- 0.92 months. The drug was generally well tolerated, and we did not observe any severe drug related adverse events. CONCLUSION: Oral valganciclovir as pre-emptive antiviral therapy administrated after detection of CMV infection seems to be an effective and safe treatment in cardiac transplant recipients.

Administration, Oral↗

PubMed2004

Clinical results with an ePTFE inflow conduit for mechanical circulatory support.

BACKGROUND: Neurologic complication is an adverse event associated with mechanical circulatory support. To decrease the incidence of embolic cerebrovascular accidents (CVA) during support with the Novacor left ventricular assist system (LVAS), an expanded polytetrafluoroethylene (ePTFE) inflow conduit has been developed and introduced clinically. METHODS: Using clinical data from Europe and Canada, we conducted a retrospective analysis of the incidence of embolic CVA with the ePTFE inflow conduit (n=88) in comparison with the previously used polyester inflow conduits (n=310, including Vascutek n=155 and Cooley n=155). We calculated freedom from embolic CVA, risk reduction for embolic CVA, and linearized rates of embolic CVA. RESULTS: A significant decrease in the incidence of embolic CVA was demonstrated with the ePTFE conduit (ePTFE 10% vs polyester 23%, p=0.002). Kaplan-Meier analysis of freedom from embolic CVA at 180 days after implantation was 86% for the ePTFE group vs 72% for the polyester group (log-rank test, 0.0185). We also found an associated risk reduction of 55% in CVA occurrence in the ePTFE group when compared with the Polyester group (hazard ratio, 0.445; 95% confidence limit, 0.222-0.890; p=0.0221). Linearized CVA rates also were decreased at all time intervals after implantation in the ePTFE group. CONCLUSIONS: Preliminary clinical results with the newly introduced ePTFE inflow conduit provide compelling evidence that the ePTFE conduit material significantly decreases thromboembolic complications during mechanical circulatory support with the Novacor LVAS.

Adolescent↗

PubMed2004

Weaning of rotary blood pump recipients after myocardial recovery: a computer study of changes in cardiac energetics.

BACKGROUND: Weaning of patients from mechanical cardiac support after myocardial recovery has always involved multiple, interacting factors, particularly the training of the myocardium during reduction of pump flow. Rotary pumps offer training advantages when support flow is reduced, even to nearly zero. We report a computer analysis that evaluates the work required of the heart during partial unloading and removal of rotary pumps. METHODS AND RESULTS: A computer model of the assisted circulation, previously implemented in MATLAB (The MathWorks Inc, Natick, Mass), has been augmented with a model of the MicroMed DeBakey ventricular assist device (MicroMed Technology, Inc, Houston, Tex). Flow, pressure patterns, and external work (pressure-volume area, calculated as the area of the ventricular pressure-volume loop [external work] plus potential energy) were calculated for nonassisted and various continuously assisted patients. Under low-flow conditions, the heart imposes an oscillating forward-backward flow through the non-occlusive rotary pump, causing an increase in ventricular work. Thus, an assist flow of 1 to 1.5 L/min requires work equivalent to that of the unsupported heart. At 60% contractility, the nonassisted pressure-volume area is 1.10 Ws/beat, and the potential energy is 0.38 Ws/beat. At a Qpump of 1 L/min, the pressure-volume area is 1.21 Ws/beat, and the potential energy is 0.37 Ws/beat. At a Qpump of 3 L/min, the pressure-volume area is 0.93 Ws/beat, and the potential energy is 0.29 Ws/beat. These conditions cannot be achieved with pulsatile systems. CONCLUSION: During weaning and retraining, an implanted rotary pump can provide a workload to the heart like that in the nonassisted situation, thus increasing the predictability of weaning and reducing the risk of reiterating heart failure.

Cardiovascular System↗

PubMed2004

Development of a suction detection system for axial blood pumps.

Axial flow blood pumps for cardiac assistance have proven their clinical viability and benefit in recent years. However, the clinical systems to date have no direct mechanism to decrease pump speed when adequate supply is not available. This may lead to ventricular collapse or increase the probability of hemolysis and thrombotic risks. Based on various experiences with left ventricular assist device (LVAD) patients in various states of recovery, at implant, in the intensive care unit, in the standard ward, and during physical exercise, 11 different algorithms were developed for the automatic detection of ventricular suction. These detection algorithms analyze the flow pattern for the presence of distinct suction indicators. For selection and optimization of the algorithms, 1000 records from approximately 100 patients were collected. Each record contains 5 s of pump flow, current, and arterial pressure. Three experts classified these records in terms of suction probability and other abnormalities. The optimization was developed in Matlab, capable of solving a fifth-dimensional optimization problem with 256 different algorithm combinations. The optimization resulted in a set of 6 algorithms, each with specific thresholds. The system detects 100% of the known suction events with 0.28% of false-positive interpretations. If tuned to avoid any false-positive detection, 90.7% of the certain events would be detected. A strategy for the development of a robust suction detection system for axial blood pumps was found. This system will be integrated into an automatic pump speed control system to provide adequate perfusion for the LVAD recipient, without excessive unloading of the ventricle.

Algorithms↗

PubMed2004

Automatic system for noninvasive blood pressure determination in rotary pump recipients.

In patients with implanted rotary pumps, the arterial pressure pulsatility is usually far lower than in normal individuals. Depending on the remaining degree of pulsatility, cuff-based systems such as the classical Riva-Rocci-determination of arterial blood pressure and correlated sounds or pressure measurements based on cuffpressure oscillations become inaccurate or even impossible. Therefore, a system was developed which evaluates the flow in the radial artery using an ultrasound wristwatch sensor, and this additional information is used for pressure determination. A computerized data acquisition and cuff-control system based on a PC using Matlab software, a wristwatch ultrasound device, and a compressor-driven pressure cuff was set up. The cuff was controlled for automatic inflation and deflation cycles. Cuff pressure and arterial flow was recorded. Several algorithm strategies were developed, which gave data for systolic blood pressure and heart rate together with a reliability index for data quality. Finally, the new algorithms were implemented in a microcontroller system. Comparisons with invasive measurements showed excellent correlation with systolic blood pressure (mean deltaP -0.3 mm Hg, n = 28). During exercise of rotary pump patients and therefore enhanced pulsatility the difference from manual evaluation was -2.1 mm Hg (n = 18). In conclusion, adaptation of the classical cuff-pressure method with ultrasound evaluation of peripheral flow allows reliable determination of blood pressure in patients with low pulsatility resulting from implanted rotary cardiac assist pumps. By development of a wristwatch sensor and an automatic control system a robust method for daily use could be developed.

Blood Pressure↗

PubMed2003

Quantitative analysis of peroxisome proliferator-activated receptor gamma (PPARgamma) expression in arteries and hearts of patients with ischaemic or dilated cardiomyopathy.

PPARgamma, a nuclear transcription factor, is expressed in various cells within the vasculature and in cardiomyocytes. It has been suggested that PPARgamma is involved in atherogenesis and in cardiac hypertrophy. Therefore, we sought to quantify PPARgamma mRNA in coronary arteries, the aorta and left ventricular specimens from patients with ischaemic (CHD) and dilated cardiomyopathy (CMP). Using real-time PCR, we were able to demonstrate the expression of PPARgamma in all of the human specimens. The lowest expression of PPARgamma was detected in the aorta specimens of both groups (this was set to one). In comparison, the expression in coronary arteries was 2.32-fold in CHD- and 3.78-fold in CMP specimens and in the left ventricle specimens, 2.12-fold in CHD- and 3.51-fold in CMP. Samples from CHD patients showed a higher expression of PPARgamma in all of the samples compared to those from CMP patients (aorta: 1.99-fold; coronary arteries: 1.35; left ventricles: 1.23). PPARgamma levels were not significantly correlated to CD 36 expression values in any group, suggesting that higher levels of PPARgamma are not principally due to increased PPARgamma expression in macrophages. This was confirmed by immunohistochemical analysis, which showed that PPARgamma is also located in the smooth muscle layer and in cardiomyocytes. In conclusion, our observations of increased PPAR mRNA expression in the coronary arteries and left ventricles from CHD and CMP patients suggest an important function of this nuclear receptor in the pathogenesis of heart disease.

Adult↗

PubMed2002

The peroxisome proliferator-activated receptor gamma (PPARgamma) is highly expressed in human heart ventricles.

Peroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand activated transcription factor which regulates gene expression in various tissues. PPARgamma was primarily found to be associated with lipid and glucose metabolism. Recent experimental studies provided evidence that PPARgamma is also expressed in the arterial wall and in cardiomyocytes and described PPARgamma as a transducer of antihypertropic signaling in the heart. This comparative study sought to investigate whether PPARgamma is differently expressed in the aorta, coronary arteries and left ventricle specimens derived from healthy heart donors (n = 5). By using quantitative PCR, we found that PPARgamma is expressed in all of the human specimens with the by far highest expression (5.01-fold) in the left ventricles compared to aorta, whereas no significant difference was detected between coronary arteries (0.93-fold) vs. aorta. Furthermore, especially great interindividual variations were observed in PPARgamma expression in aorta, and to a lesser extent, in coronary arteries and left ventricle specimens. In conclusion, our data argue for the prominent role of PPARgamma in the human heart, particularly in the normal left ventricle.

Adult↗

PubMed2002

Interaction of the cardiovascular system with an implanted rotary assist device: simulation study with a refined computer model.

In recent years, implanted rotary pumps have achieved the level of extended clinical application including complete mobilization and physical exercise of the recipients. A computer model was developed to study the interaction between a continuous-flow pump and the recovering cardiovascular system, the effects of changing pre- and afterloads, and the possibilities for indirect estimation of hemodynamic parameters and pump control. A numerical model of the cardiovascular system using Matlab Simulink simulation software was established. Data of circulatory system modules were derived from patients, our own in vitro and in vivo experiments, and the literature. Special care was taken to simulate properly the dynamic pressure-volume characteristics of both left and right ventricle, the Frank-Starling behavior, and the impedance of the proximal vessels. Excellent correlation with measured data was achieved including pressure and flow patterns within the time domain, response to varying loads, and effects of previously observed pressure-flow hysteresis in rotary pumps. Potential energy, external work, pressure-volume area, and other derived heart work parameters could be calculated. The model offers the possibility to perform parameter variations to study the effects of changing patient condition and therapy and to display them with three-dimensional graphics (demonstrated with the effects on right ventricular work and efficiency). The presented model gives an improved understanding of the interaction between the pump and both ventricles. It can be used for the investigation of various clinical and control questions in normal and pathological conditions of the left ventricular assist device recipient.

Computer Simulation↗

PubMed2002

The University of Vienna experience in heart transplantation.

Since the University of Vienna Cardiac Transplant Program began in 1984, 892 heart transplant procedures have been performed through the end of 2001. One- and five-year survival has increased steadily over time to 80% and 75%, respectively, in the most recent cohort. Ten-year survival is 55%. Over the past 10 years our program has seen dramatic changes in patient selection, accepting now patients with more risk factors (age, diabetes, elevated pulmonary resistance,..). Developments in immunosuppression have decreased the incidence of infection, rejection and graft arteriosclerosis continuously. Our program continues to pursue novel strategies to improve the survival and quality of life of our heart transplant patients.

Adolescent↗

PubMedDate not supplied

Emergency reinforcement of cracked paracorporeal blood pumps.

In a patient with biventricular paracorporeal cardiac support, severe cracks in the outer pump housing occurred for unknown reasons (possibly because of the application of solvent). Pump replacement was considered but estimated to be a very high risk for this particular patient. Therefore, it was decided to glue the ventricles. Gluing was done after pilot tests in a two stage procedure: first, with a special glue that hardens under exposure to ultraviolet light and then with a two component low exothermic epoxy resin. The procedure resulted in very satisfying stability for the remainder of the bridging period, and the patient could be transplanted successfully 59 days after the event. It is concluded that a carefully selected gluing procedure (caveats: with previously tested glue, a validated procedure, and as a last resort only) may bring less risk in such rare cases of pump cracks than a pump exchange.

Adhesives↗

PubMedDate not supplied

Neurocognitive function in patients with ventricular assist devices: a comparison of pulsatile and continuous blood flow devices.

The effect of successful ventricular assist device (VAD) implantation on neurocognitive function in terminal heart failure is uncertain. Additionally, the different impact of continuous versus pulsatile blood flow devices is unknown. A total of 29 patients (mean age 53 years), surviving implantation of a ventricular assist device as bridge to transplantation were prospectively followed (continuous flow: Micromed DeBakey, n = 11; pulsatile flow: Thoratec and Novacor, n = 18). Normative data were obtained in 40 age- and sex-matched healthy subjects (mean age 54 years). Neurocognitive function was objectively measured by means of cognitive P300 auditory evoked potentials before operation (baseline), at intensive care unit (ICU) discharge, and at the 8-week and 12-week follow-up. Before implantation of the VAD, cognitive P300 evoked potentials were impaired (prolonged) compared with age- and sex-matched healthy subjects (p < 0.001). After successful VAD implantation, P300 evoked potentials markedly improved compared with before operation (ICU discharge, p = 0.007; 8-week follow-up, p = 0.022; 12-week follow-up, p < 0.0001). Importantly, there was no difference between continuous and pulsatile VADs (before operation, p = 0.676; ICU discharge, p = 0.736; 8-week follow-up, p = 0.911 and 12-week follow-up, p = 0.397; respectively). Nevertheless, P300 peak latencies did not fully normalize at 12-week follow-up compared with healthy subjects (p = 0.012). Successful VAD implantation improves neurocognitive impairment in patients with terminal heart failure. Importantly, this effect is independent of the type of VAD (pulsatile vs. continuous blood flow).

Austria↗